(Press-News.org) On December 10, Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven biotechnology company, hosted the fourth edition of its Pharma.AI Quarterly Launch webinar, titled “Epic Year-End Recap & Q4 Winter Updates”. The event drew more than 300 registrants from universities, healthcare institutions, global pharmaceutical companies, and innovative biotech firms worldwide.
Insilico's software team showcased the recap of Pharm.AI in 2025,and the latest capabilities through live demos and real‑world case studies.
Key highlights are summarized below:
Generative Biologics
What improved in 2025:
Peptide workflows: template-based screening of peptide libraries against a receptor and manual hotspot-based pocket selection with guided peptide length and 3D analysis.
Model training: 3D-augmented models with improved performance (Pearson/Spearman +0.2–0.3), validated on the Ginkgo antibody dataset.
Generative engine: a new diffusion-based antibody model (epitope- and framework-conditioned) and configurable liability constraints with motif-based filtering.
PDB integration: fetch, auto-fix, and use PDB structures directly for experiments.
What's new in Q4:
Updated contact visualization and evaluation: Clearer, residue-level contact maps for faster interpretation of target–binder interactions.
Improved binder scoring: Refined scoring function that better integrates structural and energetic features for more accurate rankings.
New MD simulation experiment: Molecular dynamics simulations to evaluate binder stability and conformational behavior under realistic biophysical conditions.
Chemistry42/Nach01
What improved in 2025
Generative chemistry: Protein-based pharmacophore points now complement ligand-based ones, enabling diverse, protein-informed pharmacophore-guided generation.
Alchemistry 2.0: A two-stage RBFE engine (equilibrium MD + non-equilibrium switching) that delivers industry-level accuracy and massive scalability, with an interactive trajectory viewer and an upcoming absolute binding free energy module. Compared to the previous version, it improves accuracy by up to 16% and achieves a 2–4× speed-up.
MDFlow: it adds configurable MD simulations, rich trajectory analytics, and multi-format export. Together with Alchemistry 2.0, it forms a continuous physics-based workflow from free energy calculations to full MD.
ADMET Profiling: it was fully rebuilt with a new training framework, improving key regression endpoints and off-target safety assessment, including 70+ new GPCR inhibitor models, thereby extending Chemistry42’s predictive power into more complex pharmacological spaces.
Retrosynthesis: The system supports generated, custom, and sketched molecules, uses expert reaction templates and an AI Root Planner to generate selective, literature-consistent synthetic routes, integrates with eMolecules and user building-block libraries for cost-aware planning, and delivers fast, batch retrosynthesis with detailed downloadable reports and CDX scheme export.
Natch 01: A multimodal foundation model for chemistry and drug discovery. Trained on billions of molecular and textual data points, it combines language understanding and chemical intelligence for property prediction, molecular design, and scientific reasoning. Now available on AWS Marketplace for academic and industrial integration, Natch 01 will soon gain generative capabilities, further embedding it as the core of Chemistry42’s AI-driven ecosystem.
What's new in Q4:
MolSpace uses Generative Topographic Mapping (GTM) to visualize generated molecules against large public datasets through a streamlined SDF/CSV-to-analysis workflow. New density, classification, regression, and comparison landscape modes, combined with smart sampling and MDS, provide an accurate, interpretable view of both common and rare regions of chemical space.
PACE (Patent Analysis Chemical Engine) automatically extracts structured chemical data and SAR information from PDF patents by segmenting and recognizing chemical structures and SAR tables, leveraging specialized vision models and visual language models for deeper structure–activity and patent space analysis.
PandaOmics
What improved in 2025:
Expanded functionality and analytical rigor for target and biomarker discovery.
Prioritize targets with four new LLM-derived scoring metrics plus an updated ranking framework for more balanced, clinically relevant selection
The Confidence Score measures the evidence supporting the target's role in disease mechanisms.
The commercial tractability score assesses the target's market feasibility, taking into account demand and competitive landscape.
The drug ability score indicates the likelihood of successfully developing the drug.
The mechanism clarity score examines the understanding of how the intervention affects pathways and diseases.
27 scores to analyze data from multi -omics, text and other sources to support target identification and biomarker discovery projects. To enable a smooth start to any analysis. We introduced a new ranking scheme that averages five core scores to highlight well -studied targets with balanced evidence.
What's new in Q4:
Multi-entry gene support
Upload and analyze multiple molecular entities (isoforms, transcripts, or protein variants) per a single gene
Extended species support: Transcriptomic datasets from dog and cat studies can be uploaded, with automatic species recognition when using Ensembl or NCBI Entrez ID.
Strengthened data security and governance via:
Virtual Private Cloud (VPC) deployment,
Single Sign-On (SSO) integration,
Enhanced data management features,
Secure intra-organizational sharing of proprietary datasets.
The single-cell dataset viewer and gene signature will come soon.
DORA:
Deep Research compresses the journey from idea to publication‑ready report. After you enter a topic and brief context in a chat interface, it builds a focused research plan and retrieves only high‑quality sources, scored by peer‑review status, author expertise, and relevance, each with a traceable link to the original.
It then applies advanced reasoning to synthesize cross‑domain knowledge, resolve contradictions, and surface hidden questions, exposing a transparent chain of thought behind every conclusion. It produces a concise, analyst‑level report with clearly structured key insights, supporting evidence, and actionable recommendations within minutes. The report opens in DORA, where you can refine, polish, and extend it with built‑in AI tools before using it for decisions or publication.
MMAI GYM for Science:
MMAI GYM is a place where you can send any AI model to train and become an expert in real-world drug development tasks with high-performance. It combines proprietary multi‑omics datasets, patents, papers, clinical readouts, and domain‑specific reinforcement learning to teach models how to work natively with biochemical formats, understand complex R&D tasks and operate constraints of biology, safety, efficacy, and synthesis. Dramatically boosts the biological and chemical intelligence of any causal or frontier LLM, delivering up to 10× performance gains on key drug discovery benchmarks.
In 2016, Insilico first described the concept of using generative AI for designing novel molecules in a peer-reviewed journal, laying the foundation for the commercially available Pharma.AI platform. Since then, Insilico has continued to integrate technical breakthroughs into the Pharma.AI platform, which is now a generative AI-powered solution encompassing biology, chemistry, medicine development, and scientific research. Powered by Pharma.AI, Insilico has nominated over 20 developmental/preclinical candidates (DC/PCC) in its comprehensive portfolio of more than 30 assets since 2021, received IND clearance for 10 molecules, and completed multiple human clinical trials for two of the most advanced pipelines, with positive results announced.
By integrating the technologies of AI and automation, Insilico has demonstrated a significant efficiency boost compared to traditional drug discovery methods (often requiring 2.5-4 years), as announced in the recent key timeline benchmarks for internal DC programs from 2021 to 2024: the average time to DC is 12-18 months, with 60-200 molecules synthesized and tested per program
About Insilico Medicine
Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-edge automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs, including fibrosis, oncology, immunology, pain, obesity, and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across various industries, including advanced materials, agriculture, nutritional products, and veterinary medicine.
For more information, please visit www.insilico.com.
END
Insilico Medicine’s Pharma.AI Q4 Winter Launch Recap: Revolutionizing drug discovery with cutting-edge AI innovations, accelerating the path to pharmaceutical superintelligence
2025-12-19
ELSE PRESS RELEASES FROM THIS DATE:
Nanoplastics have diet-dependent impacts on digestive system health
2025-12-19
Plastics are not inert: they gradually break into fragments over time, forming micro- and then nanoplastics (i.e., particles <1 μm in size). Nanoplastics are found in drinking water and foods packaged in plastic. This reality suggests that humans may be ingesting appreciable quantities of nanoplastics to which the gut is highly exposed. Yet, we have a limited understanding of how nanoplastics affect digestive system health. Additionally, to date, studies on this topic have employed commercial particles, which often contain additives. In the study published in Environmental Science: Nano, the research team specifically ...
Brain neuron death occurs throughout life and increases with age, a natural human protein drug may halt neuron death in Alzheimer’s disease
2025-12-19
AURORA, Colo. (Dec. 19, 2025) – Scientists at the University of Colorado Anschutz have discovered that while brain neuron changes, including cell loss, may begin in early life, a drug long-approved for other conditions might be repurposed to slow this damage, offering new hope for those with Alzheimer’s disease (AD) and other cognition issues.
The study was published today in the journal Cell Reports Medicine.
“This drug improved one measure of cognition and reduced a blood measure of neuron death in people with AD in a relatively short period of time in its first clinical trial,” said the study’s senior author Professor Huntington Potter, ...
SPIE and CLP announce the recipients of the 2025 Advanced Photonics Young Innovator Award
2025-12-19
BELLINGHAM, Washington, USA — SPIE, the international society for optics and photonics, and Chinese Laser Press (CLP) have announced the recipients of this year’s Advanced Photonics Young Innovator Award. The award honors emerging researchers by recognizing outstanding papers published in the SPIE-CLP journal Advanced Photonics over the past five years.
The seven recipients represent a diverse range of groundbreaking research that is shaping the future of optics and photonics:
Peng Chen, Nanjing University, for "Liquid crystal integrated metalens with tunable chromatic ...
Lessons from the Caldor Fire’s Christmas Valley ‘Miracle’
2025-12-19
In what came to be called the “Christmas Valley miracle,” the Lake Tahoe Basin communities of Christmas Valley and Meyers were spared in late August 2021 when the massive Caldor Fire entered the basin, burning more than 222,000 acres and forcing roughly 30,000 people to evacuate during one of the hottest, driest summers on record. Outside of the Lake Tahoe Basin, the fire destroyed over 1,000 structures, many of them homes.
Decades of fuel-reduction treatments conducted by federal, state and local land managers to protect people’s communities well before the fire are widely credited for ...
Ant societies rose by trading individual protection for collective power
2025-12-19
Would you rather fight a horse-sized duck or 100 duck-sized horses?
The famous question, though implausible, reflects a ubiquitous tradeoff between quantity and quality. Now, a new study shows that this dilemma operates in biology at the evolutionary scale.
Research published on December 19, 2025, in the journal Science Advances found that certain ant species structure their colonies by favoring quantity over quality. These species invest less into each individual’s cuticle—the protective layer of the exoskeleton—which liberates nutritional resources ...
Research reveals how ancient viral DNA shapes early embryonic development
2025-12-19
Transposable elements are stretches of DNA that can move around the genome. Many of these DNA sequences originate from long ago, when viruses inserted their genetic material into our ancestors’ genomes during infection. Today, these viral transposable elements make up around 8-10% of the mammalian genome.
Once disregarded as “junk” DNA, we now know that many transposable elements play an important role in influencing how genes are turned on ...
A molecular gatekeeper that controls protein synthesis
2025-12-19
The protein factories in our cells – so-called ribosomes – have a central task: during a process known as translation, amino acids are linked together according to messenger RNA, forming a growing peptide chain that later folds into a functional protein.
However, before a newly emerging protein can even begin to fold, it must be processed and transported to the correct location within the cell. As soon as it emerges from the ribosome, enzymes can remove its initial amino acid, attach small chemical groups, or determine to which cellular compartments the ...
New ‘cloaking device’ concept to shield sensitive tech from magnetic fields
2025-12-19
University of Leicester engineers have unveiled a concept for a device designed to magnetically ‘cloak’ sensitive components, making them invisible to detection.
A magnetic cloak is a device that hides or shields an object from external magnetic fields by manipulating how these flow around an object so that they behave as if the object isn’t there.
In a new study for Science Advances, a team of engineers at the University of Leicester have demonstrated for the first time that practical cloaks can be engineered using superconductors and soft ferromagnets in forms that can be manufactured.
Using computational and theoretical techniques ...
Researchers show impact of mountain building and climate change on alpine biodiversity
2025-12-19
In a study published in Science Advances on December 19, researchers from Xishuangbanna Tropical Botanical Garden (XTBG) of the Chinese Academy of Sciences, along with collaborators from international institutions, explored the impact of mountain building and climate cooling over 30 million years across five major mountain systems in the Northern Hemisphere and revealed that these processes are key drivers of the rich plant diversity found in the Earth's alpine biome.
Mountain regions harbor a disproportional share of the world's plant species, but the processes responsible for assembling this diversity over deep time have remained unclear. ...
Study models the transition from Neanderthals to modern humans in Europe
2025-12-19
Using a specially developed simulation model, researchers at the University of Cologne have traced and analysed the dynamics of possible encounters between Neanderthals and anatomically modern humans on the Iberian Peninsula during the Palaeolithic period for the first time. Between approximately 50,000 and 38,000 years ago, the first anatomically modern humans arrived in Europe, where they encountered Neanderthal populations. The team analysed the respective settlement areas and the movement patterns of both groups. Were there any interactions between the groups, and did they mix? And how were population dynamics influenced by climatic events?
The ...